Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
Study sponsor: CG Oncology, Inc. · CGON
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-03-07Actual
Enrollment · participants35Actual
Source updated2024-09-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.